Claims for Patent: 10,973,870

Summary for Patent: 10,973,870

Title:	Methods of treating prostate cancer with GnRH antagonist
Abstract:	The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Inventor(s):	Olesen; Tine Kold (New York, NY), Persson; Bo-Eric (St. Prex, CH), Cantor; Per (Charlottenlund, DK), van der Meulen; Egbert A. (Dalby, SE), Jensen; Jens-Kristian Slott (Bagsvaerd, DK)
Assignee:	Ferring B.V. (Hoofddorp, NL)
Application Number:	16/851,179
Patent Claims:	1. A method of treating locally advanced prostate cancer in a subject, comprising: choosing a dosing regimen of degarelix over gonadotrophin releasing hormone (GnRH) agonist treatment to decrease the likelihood of developing a musculoskeletal disorder or a connective tissue disorder compared to GnRH agonist treatment when treating prostate cancer in the subject; and administering the dosing regimen of degarelix of an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein following the initial dose, the maintenance dose is administered once every 20-36 days thereafter. 2. The method of claim 1, wherein the subject is less than 65 years old. 3. The method of claim 1, wherein the treatment provides a decreased likelihood of developing or experiencing an increase in arthralgia compared to the treatment with the GnRH agonist. 4. The method of claim 1, wherein the treatment provides a decreased likelihood of developing or experiencing an increase in muscle stiffness compared to the treatment with the GnRH agonist. 5. The method of claim 1, wherein the initial dose is 240 mg of degarelix and the maintenance dose is about 80 mg of degarelix, wherein the maintenance dose is administered once every approximately 28 days of treatment. 6. The method of claim 1, wherein the initial dose of degarelix is administered as two subcutaneous injections. 7. The method of claim 1, wherein the maintenance dose of degarelix is administered monthly. 8. The method of claim 1, wherein the GnRH agonist is leuprolide. 9. The method of claim 1, wherein the subject has a body mass index of less than 30 kg/m.sup.2. 10. The method of claim 1, wherein the initial dose of degarelix is administered at a concentration ranging from 5 mg/mL to 40 mg/mL. 11. The method of claim 1, wherein the initial dose of degarelix is administered at a concentration of 40 mg/mL. 12. The method of claim 1, wherein the maintenance dose of degarelix is administered as a single injection. 13. The method of claim 1, wherein the maintenance dose of degarelix is administered at a concentration ranging from 5 mg/mL to 40 mg/m L. 14. The method of claim 1, wherein the maintenance dose of degarelix is administered at a concentration of 20 mg/m L. 15. A method of treating locally advanced prostate cancer in a subject comprising: choosing a dosing regimen of degarelix over leuprolide treatment to decrease the likelihood of developing a musculoskeletal disorder or a connective tissue disorder compared to leuprolide treatment when treating prostate cancer in the subject; and administering the dosing regimen of degarelix of an initial dose of 160-320 mg of degarelix to the subject and a maintenance dose of 60-160 mg of degarelix to the subject, wherein following the initial dose, the maintenance dose is administered once every 20-36 days thereafter.